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Objective: Endovascular treatment of abdominal aortic aneurysm (AAA) is associated with beneﬁts over open surgery, yet
limitations remain with current endovascular devices. This study was performed to assess outcomes of AAA repair with
the Aptus endograft and EndoAnchors (Aptus Endosystems, Sunnyvale, Calif).
Methods: This prospective, multicenter, single-arm investigational device exemption trial was conducted at 25 sites in the
United States. A total of 155 patients were enrolled in the trial (mean age, 73 6 8 years; male, 93.5%; mean AAA
diameter, 53.6 6 7.9 mm). The Aptus endograft is a two-component system: a multilumen, modular endograft with two
docking limbs (Aptus Endograft System) and the Heli-FX Aortic Securement System comprising an electronically
controlled applier (Heli-FX Applier) with helical EndoAnchors provided in a cassette and a deﬂectable sheath (Heli-FX
Guide) designed for delivery of the applier to the target location for EndoAnchor implantation. The main eligibility
criteria included proximal neck length of $12 mm, diameter of 19 to 29 mm, and infrarenal angulation of #60 degrees.
The primary safety end point was freedom from major adverse events at 30 days, and the primary effectiveness end point
was successful aneurysm treatment at 12 months. Thrombus-related events (TRE) were deﬁned as limb occlusion or
thromboembolism from the endograft. Subjects were observed for a median of 4.2 years, with imaging end points
analyzed by a core laboratory and adverse events adjudicated by a clinical events committee.
Results: Among 155 enrolled subjects, 153 (98.7%) underwent successful implantation of theAptus endograft and amedian
of ﬁve EndoAnchors; two subjects were converted to open surgical repair during the initial procedure. Overall, the primary
safety andeffectiveness endpointsweremet in98.1%and97.4%of the subjects, respectively.Aneurysm-relatedmortalitywas
0.6%,withonepostdischarge cardiacdeath18days after implantation.TherewerenoAAAruptures.Therewereno fractures
of stents or EndoAnchors. There was one type I endoleak and one type III endoleak. Stent graft migration was noted in ﬁve
subjects, none associated with sac enlargement, type I endoleak, or EndoAnchor dislocation from the endograft. AAA sac
shrinkage of$5 mm at 1, 2, and 3 years was observed in 60.3%, 72.9%, and 81.7%, respectively. Sixty-one subjects (39.4%)
experienced 113 TRE, associatedwith 80 reinterventions (in 58 subjects) unassociated with limb loss or death. A root cause
analysis of TRE identiﬁed small, out-of-speciﬁcation docking limbs with graft infolding and high local shear, resulting in
thrombus formation within the endograft with subsequent distal embolization in some cases.
Conclusions: Early results of the Aptus endograft trial met its safety and effectiveness end points; however, a high rate of
TRE was observed because of manufacturing discrepancies. The ﬁndings conﬁrm a low rate of type I and type III
endoleaks, migration, and non-TRE reintervention with a high rate of aneurysm sac regression during midterm follow-
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Fig 1. The proximal aspect of the main body, with EndoAnchors
penetrating the graft through the interstices of the proximal stent
ring.
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276 Mehta et al August 2014Abdominal aortic endografts have been commercially
available in the United States since 1999, and during the
next decade, endovascular aneurysm repair (EVAR) sup-
planted open surgery for most patients with abdominal
aortic aneurysm (AAA).1 Randomized clinical trials and
population-based studies demonstrated a reduction in early
morbidity and mortality for EVAR compared with open
surgical AAA repair.2-5 The paradox of an early mortality
advantage for EVAR counterbalanced by late survival loss
appears in part to be due to a high rate of secondary rein-
terventions and even aneurysm rupture after EVAR.6,7
Persistent endoleaks, endograft migration, limb occlusion,
and aneurysm sac enlargement continue to plague
EVAR.8-11
The Aptus endograft with EndoAnchors (Aptus Endo-
systems, Sunnyvale, Calif) is unique in its use of endovascu-
lar anchors that are independent of the endograft itself for
the device ﬁxation at the proximal aortic neck. The Aptus
endograft with EndoAnchors was designed to overcome
some of the limitations of currently available devices for
treatment of AAA. The use of active ﬁxation with EndoAn-
chors at the proximal attachment site allows the use of a
lower radial force proximal stent, with the potential to
reduce early and late aortic neck complications including
neck dilation, endoleak, and migration. After the comple-
tion of a feasibility trial, a U.S. investigational device
exemption premarket approval study was begun.12 The
purpose of this study was to evaluate the safety and effec-
tiveness of the Aptus endograft and EndoAnchors for treat-
ment of AAA.METHODS
The device. The Aptus AAA Endovascular Repair
System comprises two components: a modular bifurcated
endograft that uses two docking limbs (Aptus Endograft
System) and the Heli-FX Aortic Securement System
comprising an electronically controlled applier (Heli-FX
Applier) with helical EndoAnchors provided in a cassette
and a deﬂectable sheath (Heli-FX Guide) designed for
delivery of the applier to the target location for EndoAn-
chor implantation. The endograft has a short proximal
stent with relatively low radial force at the top of the main
body for sealing and the EndoAnchors for ﬁxation (Fig 1).
The main body of the endograft is composed of woven
polyester fabric and a proximal nitinol self-expanding
sealing stent. Each limb is fully supported with a nitinol
self-expanding stent running the length of the graft. The
helically shaped EndoAnchors are manufactured from
MP35N-LT (nickel-cobalt-chromium alloy) and are
approximately 4.5 mm in length. The low-proﬁle delivery
system for the endograft comes in two sizes: 16F outer
diameter for 22-, 24-, and 26-mm-diameter main body
devices and all iliac lumens; and 18F outer diameter for
the 29- and 32-mm-diameter main body devices. The
EndoAnchor delivery system has an outer proﬁle of 16F.
The system is described in greater detail in the feasibility
trial publication.12The endograft implantation procedure begins with
standard femoral or iliac artery access and introduction of
the main body delivery system. Once it is at the desired
aortic level, the main body is partially deployed by releasing
the proximal stent, unsupported main body, and contralat-
eral gate, while the proximal stent and ipsilateral gate are
still tethered to the delivery catheter to stabilize the endo-
graft until EndoAnchor ﬁxation is achieved. After cann-
ulation of the contralateral gate, the Heli-FX Guide is
advanced through the contralateral access artery and posi-
tioned within the aortic neck. Directing the guide toward
the desired location for EndoAnchor implantation, the
Heli-FX Applier is advanced through the guide until it is
in contact with the endograft, and the EndoAnchor is
deployed under ﬂuoroscopic visualization. In this manner,
EndoAnchors are implanted around the circumference of
the proximal neck, at the physician’s discretion. The
EndoAnchor is designed to penetrate the endograft and
aortic wall to reach the adventitia. The contralateral limb
is introduced and deployed before the completion of
main body deployment. After release of the main body
and removal of its delivery system, endograft implantation
is completed by introduction and deployment of the ipsilat-
eral iliac limb.
Study design. This prospective, multicenter, single-
arm study was performed at 25 U.S. investigative sites
under a Food and Drug Administration investigational
device exemption. The study was conducted in accordance
with Good Clinical Practice guidelines and was approved
by the Food and Drug Administration and each center’s
Institutional Review Board. Written informed consent was
obtained from each subject. Anatomic eligibility criteria
included proximal neck length of $12 mm, diameter of
19 to 29 mm, and infrarenal angulation of #60 degrees
(Table I). Subjects were observed with computed tomo-
graphy (CT) imaging at 1, 6, and 12 months and then
yearly thereafter through 60 months after implantation.
Table I. Eligibility criteria
Inclusion criteria
1. Age 21 years or older
2. Male or nonpregnant female patient; if a woman with childbearing potential, pregnancy test result must be negative before enroll-
ment into the study
3. Willing and able to give informed consent
4. Infrarenal AAA with a maximum diameter $4.5 cm
5. Infrarenal AAA with at least 12-mm-length of nonaneurysmal proximal neck
6. Infrarenal AAA with a proximal neck internal diameter between 19 and 29 mm
7. Infrarenal AAA with an internal diameter at the aortic bifurcation $18 mm
8. Infrarenal AAA with an angle of #60 degrees relative to the long axis of the aorta
9. Bilateral iliac artery distal ﬁxation sites $10 mm in length. The resultant repair should preserve patency in at least one hypogastric
artery.
10. Bilateral iliac arteries with an internal diameter between 9 and 20 mm
11. Bilateral femoral/iliac arteries with morphology (minimal thrombus, calcium, or tortuosity) compatible with standard vascular access
techniques, and vessel size must accommodate a 16F (5.3 mm) or 18F (6.0 mm) delivery system
12. Candidate for elective surgical AAA repair based on the opinion of the investigator
13. Patient agrees to return to the treating investigator for all scheduled follow-up visits and is capable of returning to the hospital for
follow-up
14. Life expectancy >2 years
Exclusion criteria
1. Myocardial infarction within past 10 weeks
2. Active systemic infection
3. Ruptured or leaking AAA
4. Mycotic or inﬂammatory AAA
5. Connective tissue disorders
6. Concomitant thoracic or thoracoabdominal aortic aneurysms
7. Requires emergent AAA surgery
8. Previous AAA repair
9. Patients with a body habitus that would prevent imaging required by the study
10. Patient has signiﬁcant comorbid conditions that, in the opinion of the investigator, pose undue risk of general anesthesia or endo-
vascular surgery
11. Patient requires additional planned major procedure at the time of AAA repair or within 30 days before or after AAA repair
12. Dialysis dependent renal failure or creatinine concentration >2.5 mg/dL
13. Allergy to or intolerance of radiopaque contrast agents that cannot be adequately pretreated or would prevent imaging required by
the study
14. Patients with a known sensitivity or allergy to polyester, nickel, titanium, tantalum, chromium, molybdenum, or cobalt
15. Patients who cannot discontinue oral anticoagulation or antiplatelet therapy at the time of the study procedure
16. Patients with history of bleeding diathesis or hypercoagulable condition
17. Patients with thrombus, calciﬁcation, or plaque $2 mm in thickness or $50% (180-degree) continuous coverage of the vessel
circumference in the intended seal zone
18. Patients with irregularly shaped calciﬁcation or plaque that may compromise the ﬁxation and sealing at the proximal or distal
implantation sites
19. Mental impairment or other conditions that may not allow the subject to understand the nature, signiﬁcance, or scope of the study
20. Participation in another trial of an investigational drug or device that has not yet completed follow-up requirements
AAA, Abdominal aortic aneurysm.
JOURNAL OF VASCULAR SURGERY
Volume 60, Number 2 Mehta et al 277The primary safety end point of the study was the per-
centage of subjects experiencing one or more major
adverse events (MAE) occurring within 30 days of the in-
dex procedure. MAE were deﬁned with the criteria speci-
ﬁed by the Society for Vascular Surgery Outcomes
Committee in the Lifeline Registry, deﬁned by the occur-
rence of death, myocardial infarction, stroke, renal failure,
respiratory failure, or paralysis.13
The primary effectiveness end point of the study was
the composite of delivery success and absence of type I
or type III endoleaks requiring intervention after the index
procedure, migration, open surgical conversion, or aneu-
rysm rupture within 1 year of the index procedure. Delivery
success was deﬁned as successful implantation of the
Aptus endograft with a main body and two iliac limbs
and delivery of at least two EndoAnchors at an appropriate
treatment site within the proximal aortic neck. Benchtesting demonstrated that displacement force with two or
more EndoAnchors was similar to that achieved with a sur-
gically constructed anastomosis.14
Aneurysm sac enlargement or shrinkage was deﬁned
when the maximum sac diameter changed by more than
5 mm, and migration was deﬁned by endograft stent move-
ment of more than 10 mm, both relative to the 30-day CT
scan as read by the core laboratory. Adverse events were
adjudicated by an independent Clinical Events Committee;
this included all thrombus-related events (TRE), deﬁned as
any graft limb occlusions or distal thromboembolic event
thought to originate from the endograft. Integrity of the
EndoAnchors and endograft stents was assessed on the
plain ﬁlm radiographs by the core laboratory. Unantici-
pated adverse device effects were deﬁned as those serious
adverse events associated with the device that were not pre-
viously identiﬁed in nature, severity, or incidence. A Data
Table II. Baseline characteristics of the subjects
Age, years
Mean 6 standard deviation 73 6 8
Median 73
Minimum, maximum 57, 91
Gender, n/N (%)
Male 145/155 (93.5)
Female 10/155 (6.5)
Comorbid conditions, n/N (%)
Coronary artery disease 88/155 (56.8)
Previous myocardial infarction 52/155 (33.5)
Congestive heart disease 11/155 (7.1)
Valvular heart disease 15/155 (9.7)
Chronic obstructive pulmonary disease 34/155 (21.9)
History of smoking 124/155 (80.0)
Current smoker 34/155 (21.9)
Stroke 17/155 (11.0)
Renal insufﬁciency 9/155 (5.8)
Peripheral arterial disease 31/155 (20.0)
Table III. Anatomic characteristics of the subjects as
determined by the core laboratory
Neck length, mm
Mean 6 standard deviation 22.1 6 10.8
Median 19.9
Minimum, maximum 2.0, 50.0
Neck angle, degrees
Mean 6 standard deviation 32.1 6 14.0
Median 30.5
Minimum, maximum 3.1, 71.7
Neck diameter, mmdlanding zone
Mean 6 standard deviation 22.8 6 2.5
Median 22.5
Minimum, maximum 17.5, 29.5
Aneurysm maximum diameter range, n/N (%)
<45 mm 0/155 (0.0)
45-49 mm 43/155 (27.7)
50-59 mm 85/155 (54.8)
60-69 mm 21/155 (13.5)
70-79 mm 5/155 (3.2)
80-89 mm 0/155 (0.0)
$90 mm 1/155 (0.6)
Minimum access vessel diameter, mm
Mean 6 standard deviation 7.0 6 1.4
Median 7.0
Minimum, maximum 3.7, 11.0
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whether the rate of adverse events was unreasonable and
to establish monitoring criteria and time points for their
assessment. The Data Safety Monitoring Board proposed
stopping rules based on the predetermined expected fre-
quency of adverse events.
Statistical analysis. The study was designed to
demonstrate superiority of the Aptus AAA Endograft Sys-
tem in comparison to the 30-day MAE rate of 11.1% for
the 323-subject open surgical AAA repair Lifeline Registry
data set (primary safety end point)13 and to demonstrate
aneurysm treatment success greater than a performance
goal of 80% at 1 year (primary effectiveness end point).15-19
Assumptions used for sample size calculations included a
one-sided a of .025, 80% power, and withdrawal rates of
5% and 15% at 30 days and 1 year, respectively. The esti-
mated MAE rate at 30 days was 4.6% for the primary safety
end point, and the estimated treatment success for the
effectiveness end point was 90.3%. Under these assump-
tions, the sample sizes for the primary safety and effective-
ness end points were 155 and 135 subjects, respectively.
Thus, the overall sample size was driven by safety and was
set at 155 subjects.
A c2 test was used to compare categorical variables
(with Fisher exact test when the number of cases in any
group was less than ﬁve), and these are reported as percent-
ages. Continuous variables were assessed with the Student
t-test and are reported as mean 6 standard deviation
(range). For all analyses, a two-tailed P value of <.05 was
considered signiﬁcant.
RESULTS
Between September 2007 and January 2009, 155 sub-
jects were enrolled, and 153 (98.7%) were implanted with
the complete Aptus Endograft System. A single subject un-
derwent conversion to open surgical repair before the
placement of EndoAnchors after unsuccessful cannulation
of the contralateral gate. A second subject was converted
to another endovascular device after misdeployment of
the Aptus main body. Among the 155 subjects, the mean
age was 73 6 8 years (range, 57-91 years), and 145
(93.5%) were men. Aneurysms ranged in size from 4.2 to
9.4 cm, with a mean of 5.4 6 0.8 cm. The average prox-
imal aortic neck length was 22.1 6 10.8 mm, with a range
of 2 to 50 mm. The proximal neck length was <12 mm
and <10 mm in 17% and 12% of subjects, respectively.
The average infrarenal neck angulation was 32.1 6 14.0
degrees, with a range of 3.1 to 71.7 degrees.a Baseline
comorbidities and anatomic characteristics are summarized
in Tables II and III. The median length of follow-up was
3.4 years, with an interquartile range of 3.1 to 3.8 years.
A total of 155 main bodies, 332 iliac limbs, and 7 aortic
cuffs were implanted. The median number of Endo-
Anchors was ﬁve per subject, with a range of 0 to 14
(Fig 2). The average time to deploy the device wasaInvestigator-submitted data were used to determine anatomic inclusion or
exclusion. Core laboratory data are presented here.69 6 34 minutes, including 17 6 12 minutes to deploy
the EndoAnchors. The mean total procedure duration
was 135 6 60 minutes. The mean procedural blood loss
was 207 6 218 mL, with a median of 150 mL. The length
of intensive care unit stay averaged 0 6 1 day, with a range
of 0 to 5 days.
Among the 155 subjects, successful device delivery was
completed in 153 (98.7%); the two failures included one
open surgical conversion after failure to cannulate the
contralateral gate and one implantation of a nonstudy
endograft after misdeployment of an Aptus main body.
In the latter case, the Aptus endograft was released from
the delivery system before deployment of EndoAnchors,
the study device was dislodged distally into the aneurysm
sac, and a nonstudy endograft (Excluder; W. L. Gore,
Fig 2. The number of EndoAnchors (810) implanted in 154
subjects.
Table IV. Subjects experiencing one or more major
adverse events (MAE) within 30 days, 1 year, and 3 years
of index procedure
Event
Through
30 days,
n/N (%)
Through
1 year,
n/N (%)
Through
3 years,
n/N (%)
Death 1/155 (0.6) 5/155 (3.2) 15/155 (9.7)
Myocardial
infarction
2/155 (1.3) 7/155 (4.5) 10/155 (6.5)
Stroke 0/155 (0.0) 3/155 (1.9) 7/155 (4.5)
Renal failure 0/155 (0.0) 2/155 (1.3) 6/155 (3.9)
Respiratory failure 0/155 (0.0) 1/155 (0.6) 3/155 (1.9)
Paralysis 0/155 (0.0) 0/155 (0.0) 0/155 (0.0)
Any MAE 3/155 (1.9) 14/155 (9.0) 30/155 (19.4)
JOURNAL OF VASCULAR SURGERY
Volume 60, Number 2 Mehta et al 279Flagstaff, Ariz) was deployed through the study device to
complete the repair. The 30-day mortality rate was 0.6%,
with one postdischarge cardiac death that occurred
18 days after an index procedure complicated by rupture
of an iliac artery during balloon angioplasty of a graft
limb. Overall survival at 1, 2, and 3 years was 96.8%,
96.1%, and 91.6%, respectively. Freedom from aneurysm-
related mortality was 99.4% at 1 year, accounted for by
the death that occurred within 30 days of implantation.
There was one additional aneurysm-related death beyond
3 years due to hemorrhagic stroke adjudicated to be related
to warfarin prescribed to treat a pulmonary embolism sub-
sequent to an AAA-related reintervention. There were no
device-related deaths or AAA ruptures in the study. Type
I and type III endoleaks within the ﬁrst year of follow-up
were observed in one subject each. The primary effective-
ness end point of 1-year treatment success was achieved
in 151 of 155 subjects (97.4%); thus, the study met its pri-
mary effectiveness end point by exceeding the 90.3% esti-
mated rate of treatment success.
MAE occurred in three subjects (1.9%) within 30 days
and in 14 subjects (9.0%) within 1 year (Table IV). The
observed 30-day MAE rate was signiﬁcantly lower than
the 11.1% rate in the Lifeline open surgical control group
(P¼ .0003); thus, the studymet its primary safety end point.
There were no EndoAnchor or stent fractures identiﬁed
in any subject. There were no reported balloon ruptures dur-
ing inﬂation at the proximal endograft attachment site. There
was no migration of the EndoAnchors relative to the endo-
graft in any subject. Endoleaks as assessed by the core labora-
tory are reported in Table V. There was one type I endoleak
within the ﬁrst year after implantation (0.6%), for which the
subject did not meet the proximal neck inclusion criteria.
This subject underwent reintervention with placement of
four additional EndoAnchors 8 months postoperatively,
without resolution of the endoleak. Chimney grafts were
deployed in this subject 10 months thereafter, and the endo-
leak resolved. There was one type III endoleak that occurred
in a subject who had inadvertent caudal deployment of the
main body requiring placement of an aortic extender cuff dur-
ing the initial procedure (0.6%). The unanchored main body
migrated distally relative to the aortic cuff, as observed on the6-month CT scan, which also identiﬁed sac enlargement.
This subject was successfully treated 7 months after the index
procedure, with deployment of an aortouni-iliac device
within the original endograft and a femoral-femoral bypass.
Type II leaks were observed in 49 of 149 subjects
(32.9%) at 30 days and in 23 of 131 subjects (17.6%) at
1 year. Endograft migration >1 cm was reported by the
core laboratory in ﬁve subjects. Two subjects exhibited
endograft migration on the 2-year follow-up CT scan,
neither with evidence of endoleak or EndoAnchor disloca-
tion or requiring reinterventions. One of the two was asso-
ciated with signiﬁcant mural preoperative aortic neck
thrombus that might have precluded EndoAnchor penetra-
tion into the aortic wall (Fig 3). Aortic neck thrombus
>2 mm in thickness is a criterion of exclusion into the trial.
On 3-year follow-up CT imaging, two subjects demon-
strated endograft migration from the proximal ﬁxation
site. In both subjects, there was no evidence of EndoAnchor
dislocation; they remained in the same location with respect
to the endograft, and there were no demonstrable type I
endoleaks. It could not be determined whether the
EndoAnchors failed to adequately penetrate the aortic wall
on implantation, the EndoAnchors became dislodged from
the aortic wall over time, or the caudal displacement of
the endograft was attributable to aortic neck elongation
alone. A ﬁfth subject presented with migration at 4-year
follow-up, again without evidence of endoleak or EndoAn-
chor dislocation and not requiring reintervention. Aneurysm
sacs decreased in 60.3% of subjects at 1 year and in 81.7% at
3 years. Sacs enlarged in 1.5% of subjects at 1 year and in
3.7% at 3 years (Table VI). Overall, a total of ﬁve subjects
(3.2%) exhibited >5 mm sac enlargement, of which four
occurred in conjunction with type II endoleaks and one in
conjunction with the type III endoleak noted before.
Sixty-two subjects experienced 114 adverse events that
met the deﬁnition of unanticipated adverse device effects
through the median follow-up of 4.2 years. TRE accounted
for the unanticipated adverse device effects in 61 of these
62 subjects (98.4%). Overall, 32 subjects (20.6%) experi-
enced a total of 49 device-related thrombotic events within
1 year of implantation (average of 1.5 events per subject),
and 56 subjects (36.1%) experienced 104 device-related
Table V. Endoleaks as assessed by the core laboratory
Endoleak type 30 days, n/N (%) 6 months, n/N (%) 1 year, n/N (%) 2 years, n/N (%) 3 years, n/N (%)
I 0/149 (0.0) 0/140 (0.0) 0/131 (0.0a) 0/104 (0.0) 0/78 (0.0)
II 49/149 (32.9) 33/140 (23.6) 24/131 (18.3) 11/104 (10.6) 10/78 (12.8)
III 0/149 (0.0) 1/140 (0.7) 0/131 (0.0) 0/104 (0.0) 0/78 (0.0)
IV 0/149 (0.0) 0/140 (0.0) 0/131 (0.0) 0/104 (0.0) 0/78 (0.0)
V 0/149 (0.0) 0/140 (0.0) 0/131 (0.0) 0/104 (0.0) 0/578 (0.0)
Indeterminate 1/149 (0.7) 4/140 (2.9) 4/131 (3.1) 2/104 (1.9) 4/78 (5.1)
aA type I endoleak was observed on a nonprotocol-required computed tomography (CT) scan performed within the ﬁrst year after the index procedure. This
scan was not reviewed by the core laboratory and thus does not appear in the table.
Fig 3. Computed tomography (CT) images from a subject with endograft migration. A, Preoperative image of aortic
neck with signiﬁcant mural thrombus. B, Preoperative three-dimensional reconstruction. C, A 1-month image
demonstrating reasonable apposition of graft to aortic wall but poor penetration of EndoAnchors.D, A 1-month three-
dimensional reconstruction with top stent of endograft immediately caudal to the left renal artery. E, A 30-month
image demonstrating poor EndoAnchor penetration and proximal stent located in mural thrombus. F, A 30-month
three-dimensional reconstruction illustrating caudal migration of the endograft well below the left renal artery.
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Table VI. Aneurysm sac diameter change by core laboratory analysis at each follow-up time point
6 months (n ¼ 140), No. (%) 1 year (n ¼ 131), No. (%) 2 years (n ¼ 107), No. (%) 3 years (n ¼ 82), No. (%)
Decrease by >5 mm 62 (44.3) 79 (60.3) 78 (72.9) 67 (81.7)
No changea 77 (55.0) 50 (38.2) 26 (24.3) 12 (14.6)
Increase by >5 mm 1 (0.7) 2 (1.5) 3 (2.8) 3 (3.7)
aA change of #5 mm in the aneurysm sac diameter.
Fig 4. Computed tomography (CT) image of endograft limb with
irregular luminal thrombus (arrow).
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subject). Median time from implantation to ﬁrst event in
affected subjects was 355 days (interquartile range, 176-
691 days; range, 17-1477 days). The rate of limb occlusion
on a per subject basis was 4.5% (seven subjects) at 1 year
and 7.7% (12 subjects) at 3 years. Distal embolic events
linked to the endograft occurred in 15 subjects (9.7%)
within 1 year and 23 subjects (14.8%) within 3 years. Imag-
ing identiﬁed nonocclusive thrombus in association with
symptoms (or asymptomatic thrombus that was treated
prophylactically) in 15 subjects (9.7%) through 1 year and
33 subjects (21.3%) through 3 years (Fig 4).
A total of 122 secondary interventions were performed
in 74 subjects (47.7%), 92 (75.4%) of which were performed
in 58 of the 61 subjects (95.1%) with TRE (Table VII). No
TRE resulted in minor or major amputations, either at the
time of the event or as a result of treatment for the event.
Six subjects (3.29%) underwent open surgical conversion:
one during the index procedure after inability to cannulate
the contralateral gate, one for migration discovered on the
2-year follow-up CT scan, one for aortoenteric ﬁstula
remote from the location of the EndoAnchors, and three
for device occlusion (Table VIII). Three subjects (1.9%)
had implantation of a nonstudy endograft device, one after
the aforementioned misdeployment of the Aptus main
body device during the index procedure, one for endograft
limb occlusion, and one for the aforementioned type III
endoleak after disunion of the unanchored main body and
aortic extender cuff.
Endograft explantation was necessary in six subjects.
Among these, one underwent explantation at the index
procedure after inability to cannulate the contralateral
gate, mentioned previously. The other ﬁve explants were
performed for thrombotic occlusion in three subjects,
endograft migration and kinking in one subject, and aor-
toenteric ﬁstula remote from the site of EndoAnchor im-
plantation in the last subject.
TRE root cause analysis. After the identiﬁcation of
the high rate of TRE, a root cause analysis was performed.
The root cause analysis indicated that the high rate of graft-
related thrombotic events was caused by undersized
docking lumens in the main body endografts, resulting
from a manufacturing stitching process that allowed
luminal narrowing. The out-of-speciﬁcation and under-
sized docking lumens, when implanted within the ipsilat-
eral or contralateral stent graft main body docking lumen,
led to focal ﬂow lumen diameter reductions and signiﬁcant
infolding of the stent graft material. An explanted endo-
graft from an open surgical conversion demonstrated thisconstriction and infolding of the fabric within the docking
lumens (Fig 5).
We hypothesize that narrow and highly irregular
luminal surfaces resulted in a high ﬂuid shear environment
that led to platelet aggregation within the lumen, having
the potential to progress to limb occlusion or to embolize
in the distal vasculature. This was conﬁrmed in ex vivo
bench experiments using fresh male bovine blood. Worst-
case undersized docking regions were evaluated, yielding
shear rates double those observed in nonnarrowed devices
that met speciﬁcation. Thrombus formation was assessed in
main body devices with three different luminal diameters:
9.9 mm, 11.9 mm, and 13.3 mm. Each was perfused at a
similar blood ﬂow rate. The highest blood shear rate group
(9.9 mm diameter) was associated with the greatest
amount of thrombus compared with the medium-shear
(11.9 mm) and low-shear (13.3 mm) groups. Applying
these shear conditions to other marketed endografts
demonstrated similar platelet-rich thrombus formation.
Repeating the experiments with platelet-depleted blood
demonstrated no thrombus formation, supporting the hy-
pothesis that platelet-rich thrombus formation was the
cause of the high rate of TRE.
After identiﬁcation of the presumed cause of the high
frequency of TRE, the manufacturer shared the ﬁndings
with the Clinical Events Committee, the Data Safety
Table VII. Conversions and reinterventions
Procedure
to 30 days,
No. (%)
30 days to
6 months,
No. (%)
6 to 12
months,
No. (%)
12 to 24
months,
No. (%)
24 to 36
months,
No. (%)
36 to 48
months,
No. (%)
Subjects at start of interval 155 152 146 143 126 104
Conversion to open repair 1 (0.6) 0 (0) 0 (0) 1 (0.7) 2 (1.6) 2 (1.9)
Conversion to nonstudy endovascular device 1 (0.6) 0 (0.0) 1 (0.7) 0 (0) 1 (0.8) 0 (0)
TRE-related reinterventions 0 (0.0) 13 (8.6) 22 (15.1) 25 (17.5) 24 (19.0) 6 (5.8)
Other AAA-related reinterventions 3 (1.9) 0 (0.0) 5 (3.4) 10 (7.0) 7 (5.6) 3 (2.9)
Total AAA-related reinterventionsa 3 (1.9) 13 (8.6) 27 (18.5) 35 (24.6) 31 (24.6) 9 (8.7)
AAA, Abdominal aortic aneurysm; TRE, thrombus-related event.
aThe two conversions occurring within 30 days were completed during the index procedure; therefore, they are not counted in the total of “secondary”
interventions.
Table VIII. Conversions to open surgical repair or to a
nonstudy endograft during the course of study
Days
after index
procedure Event Conversion
0 Misdeployment of main
body
Implant nonstudy
device
0 Failure to cannulate gate Open surgical repair
203 Type III endoleak between
main body and aortic cuff
Aortouni-iliac device
467 Device occlusion Open surgical repair
934 Device occlusion Open surgical repair
938 Limb thrombus deposition Aortouni-iliac device
1004 Migration and subsequent
kinking
Open surgical repair
1181 Device occlusion Open surgical repair
1282 Aortoenteric ﬁstula Open surgical repair
bStatistical testing omitted because of the post hoc analysis.
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parties developed a strategy that included modiﬁcation of
the surveillance schedule with more frequent follow-up ex-
aminations with additional imaging at the discretion of the
investigator. Investigators chose numerous treatments
to address TRE in their study subjects. In evaluating treat-
ment of the ﬁrst episode of TRE in 94 limbs, covered stents
were employed in 33 limbs (35.1%), bare metal stents in 11
(11.7%), and open surgical revascularization or endograft
explant and revascularization in 17 (18.1%). Twenty-one
limbs (22.3%) underwent other interventions including
thrombectomy, thrombolysis, endarterectomy, percuta-
neous transluminal angioplasty, and native vessel stenting.
Twelve limbs (12.8%) were observed without direct inter-
vention, either with or without (10 and two limbs, respec-
tively) antithrombotic medication.
The placement of a balloon-expandable stent within
an iliac lumen in an affected docking region has the po-
tential to address part of the root cause of TRE as the
irregular luminal surface can be smoothed; however, a
diameter increase would not be obtained because of the
constriction of the undersized main body endograft
docking lumen. Covered stents may offer the potential
for better smoothing than bare metal stents. None of
the 33 limbs treated with a covered stent experiencedrecurrent TRE. By contrast, recurrences developed in
two of 11 limbs (18.1%) treated with bare metal stents
and in eight of 21 limbs (38.1%) in which the offending
endograft was not directly addressed with an intervention
(Table IX).b
DISCUSSION
The two decades after the advent of EVAR witnessed
great advances in endograft technology, operator proﬁ-
ciency, and patient selection. Early reports documented
clinical beneﬁt over traditional open surgical aneurysm
repair, with reductions in perioperative adverse events,
length of hospital stay, and time to return to baseline activ-
ity levels.20-22 Nevertheless, the longer term durability of
the procedure remains inferior to that of open surgical
repair, and early morbidity and mortality beneﬁts have
not persisted during long-term follow-up.5,6,23 As well,
the applicability of current devices is limited to patients
with relatively speciﬁc aortoiliac anatomic conﬁgurations
and access vessels of adequate diameter to accommodate
the relatively large bore delivery systems. Outcome is infe-
rior when the limits of an endograft are extended beyond
its intended use, particularly when the proximal neck is
highly angulated, short, or large in diameter.24-27
The Aptus endograft and EndoAnchors were designed
to function in tandem to offer a durable solution to prox-
imal aortic neck challenges, thereby increasing the applica-
bility of EVAR to a broader patient population. The design
concept separates sealing and ﬁxation, relying on a
conformable top stent ring without great radial force to
achieve sealing while the EndoAnchors accomplish ﬁxa-
tion. The absence of a higheradial force stent and the
use of securing EndoAnchors may reduce the incidence
of proximal aortic neck enlargement commonly encoun-
tered after EVAR, although there are scant objective data
on which to support this supposition.28 Noting the dura-
bility of open surgical aneurysm repair, the EndoAnchors
were designed to mimic a traditional surgically sutured
anastomosis. The data from this study conﬁrmed a low
rate of type I endoleak and endograft migration. Further,
aneurysm sac contraction occurred in more than 60% of
Fig 5. Infolding of graft fabric evident on an explanted device, with the histologic section at the level of the docking
limbs. The black circle is the lumen diameter when it is reconstructed from nadir to nadir; the orange circle represents
the nominal diameter.
Table IX. Treatment of thrombus-related events (TRE), by limb
Treatment Events (n ¼ 94), No. (%) Recurrent TRE, n/N (%)
Follow-up after intervention
Median (minimum, maximum)
Explant of device 3 (3.2) 0/3 (0.0) 39 (39, 42)a
Bypass revascularization 14 (14.9) 2/14 (14.3) 871 (117, 1482)
Covered stent in device 33 (35.1) 0/33 (0.0) 656 (165, 1483)
Bare metal stent in device 11 (11.7) 2/11 (18.2) 812 (531, 1463)
Stent in native artery 3 (3.2) 2/3 (66.7) 873 (414, 973)
Other intervention 18 (19.1) 6/18 (33.3) 833 (0, 1364)
Medication alone 10 (10.6) 3/10 (30.0) 1134 (269, 1324)
Total without intervention 2 (2.1) 1/2 (50.0) 739 (701, 776)b
Total with intervention 92 (97.9) 15/92 (16.3) 742 (0, 1483)
aPer protocol, subjects exit the study on completion of a 30-day follow-up after conversion.
bFollow-up is from time of TRE in limbs without intervention.
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tation, a rate that surpasses the reports of other devices and
is indirect evidence of reliable sealing. Endograft migration
was noted in just more than 3% of subjects. Neither
EndoAnchor dislocation nor a type I endoleak was recog-
nized in any of these cases. Possible root causes for endo-
graft migration without EndoAnchor dislocation include
inability of EndoAnchors to fully penetrate the aortic wall
at the time of implantation, EndoAnchor penetration
into aortic neck thrombus alone, EndoAnchor dislocation
from the aortic wall over time, and elongation of the aortic
neck. Whereas the current study deﬁned success by deploy-
ment of two or more EndoAnchors, commercially four or
six EndoAnchors are recommended, depending on the
diameter of the endograft. The primary safety and effective-
ness end points of the clinical trial were met; the Aptus sys-
tem was associated with a lower rate of MAE compared
with standard open surgical repair, and the effectiveness
of the system as measured by 1-year treatment success
was comparable to that of other marketed devices.
The rate of endograft-related thrombotic events was
unexpectedly high, although direct comparison of ratesto published data is hindered because relatively few prior
publications have rigorously searched for or reported
such events.8,29 Although it is not reﬂected in the MAE
rate, TRE were associated with signiﬁcant clinical sequelae.
All but one of ﬁve endograft explants performed postoper-
atively were required because of limb-related complications.
A root cause analysis identiﬁed the main body docking limb
sewing process and out-of-speciﬁcation lumen diameters as
the underlying problem for thromboembolism. Mating of
the iliac limbs into the smaller than anticipated docking
zones produced a diameter reduction along with infolding
of the fabric, both of which increased shear rate and turbu-
lence. Computational ﬂuid dynamics modeling suggested
that high shear rate and platelet aggregation within the
proximal iliac limbs could occur in out-of-speciﬁcation
gates. The development of platelet-rich thrombi at sites of
high shear is well known in many settings, most notably ca-
rotid stenosis, in which nonocclusive thrombi embolize
distally or progress to in situ vascular occlusion, or
both.30,31 The same phenomenon is also seen in kinked
endograft limbs or those narrowed in small aortic bifurca-
tions. A recent study demonstrated a correlation between
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graft patients.32
Design modiﬁcations were facilitated by the precise
identiﬁcation of the underlying cause of the high rate of
TRE. A new supporting suture sewing method and
enhanced quality assurance processes reduced the shear
to a level at or below that of other endograft devices. Clin-
ically, these changes appear to have reduced the rate of
TRE to very low levels, reported to be near zero in a report
of the early European experience with the newer genera-
tion devices.33
TRE did not affect the rate of primary end point vari-
ables of the study because they are a component of neither
MAE nor the effectiveness measures as recommended in
societal guidelines.16,34,35 This is not surprising because
the earlier years of EVAR focused on endoleaks, migration,
and device integrity issues. Only relatively recently has the
rate of endograft limb problems risen to the forefront. A re-
view of published rates of endograft limb occlusion reveals
a frequency ranging from 0% to 6%, depending on the
particular device and length of follow-up. Reports of
embolic complications after EVAR are scant, but two series
suggest that the frequency approximates 1%.8,29 Authors
of subsequent revisions of reporting standard documents
may consider recommending the addition of endograft-
related thromboembolic complications to the list of
MAE after EVAR. The analysis of TRE data from the cur-
rent study is likely to be generalizable to other endografts.
When TRE occur with thrombus detected in an endog-
raft, it appears that outcome is best if the problem is
directly addressed. Noninterventional management alone
was associated with a signiﬁcant rate of recurrent throm-
boembolism, and covered stents seemed to provide the
best long-term protection.
This clinical trial is limited by many of the shortcom-
ings inherent in studies performed to gain regulatory
approval for a medical device. The study population is
more limited than would be encountered once a device rea-
ches the marketplace. As such, the ﬁndings must be evalu-
ated in the context of the inclusion and exclusion criteria.
This is of particular importance in the current study
because clinicians may elect EndoAnchor use for patients
with the most challenging aortic neck anatomy, a subpop-
ulation that would have been excluded from this study.
Similar to most recent investigational device exemption
studies, this study does not include a concurrent control
group. For this reason, clinical and imaging outcome ob-
servations may not be entirely comparable to those of other
studies that employed different eligibility criteria. Any com-
parisons between the current study and other studies
should be considered in this regard.
CONCLUSIONS
The Aptus endograft with EndoAnchors is a promising
new alternative, with the potential to treat patients with
more challenging proximal aortic necks with a system
that structurally resembles a hand-sewn surgical anasto-
mosis. Whereas patients with hostile aortic neck anatomywere, for the most part, excluded from enrollment in this
study, it is axiomatic that EndoAnchors alone can be
used in commercially available endografts, and the a study
is ongoing for the stand-alone EndoAnchor indication.36
The high rates of limb thrombosis and distal thromboem-
bolism appear to have been addressed with a design modi-
ﬁcation, borne out by early clinical data. Ultimately, the
long-term outcome in patients treated with the Aptus sys-
tem must await the availability of data from ongoing and
future clinical trials that are designed to carefully assess
the risk-beneﬁt equation of endovascular repair of infrare-
nal AAA over the broad range of anatomy encountered.
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